Tackling the Disproportionate Burden of Resistant Hypertension in Black Adults

Release Date: December 19, 2023
Expiration Date: December 19, 2024

This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.

This activity is supported by an educational grant from Medtronic

Program Overview:

This activity consists of a recorded presentation at the 18th annual CMHC Annual Congress held from October 18-21, 2023, in Boston, MA. The session, “Tackling the Disproportionate Burden of Resistant Hypertension in Black Adults: Perspectives & Advances,” was presented by Keith C. Ferdinand, MD, and Debbie Cohen, MD.

Drs. Ferdinand and Cohen discussed:

• Strategies to overcome barriers to hypertension control and cardiovascular diseases.
• The definitions, current treatment, and emerging approaches for resistant hypertension.

---

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

• Recognize the prevalence and burden of resistant hypertension in high-risk individuals.
• Evaluate comprehensive factors that may contribute to resistant hypertension in high-risk individuals as a means for early evaluation and treatment intensification.
• Summarize recent results with renal denervation and emerging pharmacotherapies for resistant hypertension as highlighted in pivotal clinical trials and real-world registries.
• Identify comprehensive and individualized treatment options for high-risk individuals with resistant hypertension to optimize BP control and reduce the risk of adverse outcomes.

---

TARGET AUDIENCE

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

---

FACULTY

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine
Tulane University School of Medicine
New Orleans, LA

Debbie L. Cohen, MD
Professor of Medicine
Director of Hypertension Programs
University of Pennsylvania
Philadelphia, PA

---

JOINT PROVIDERSHIP STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION

PACE designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-23-318-H01-P. Type of activity: Application

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

DIETITIAN CONTINUING EDUCATION

This program offers 1.0 CPEUs for dietitians.

---

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 1.0 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from December 15, 2023 through December 15, 2024.

1. Review the objectives and disclosures
2. Study the educational content
3. Successfully complete activity post-test(s)
4. Complete the activity evaluation

You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For additional information about the accreditation of this activity, please visit https://partnersed.com

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

---

DISCLOSURES

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Ferdinand, faculty for this educational activity, has the following relevant financial relationships:
Consultant, Advisor, Speaker: Amgen, Novartis, Eli Lilly, Medtronic, Boehringer Ingelheim, Janssen

Dr. Cohen, faculty for this educational activity, has the following relevant financial relationships:
Advisor: CVRx
Consultant, Advisor, Speaker: Medtronic, Recor, Metavention

DISCLOSURE OF CONFLICT OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.